The DESIRE study - Psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice

European Journal of Dermatology

Volumn 19, Issue 6, 2009, Pages 581-585

  Claréus, Birgitta Wilson ^a   Houwing, Ronald ^b   Sindrup, Jens H ^c   Wigchert, Suzanne ^d  

^a Hudmottagningen   (Sweden)

^b DEVENTER HOSPITAL   (Netherlands)

^c LEO Pharma Benelux ^*  (Denmark)

^d LEO Pharma Benelux   (Netherlands)

Author keywords

Betamethasone dipropionate; Calcipotriol; Daily clinical practice; Non interventional study; Patients' satisfaction; Psoriasis

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PHOTOTHERAPY; PRESCRIPTION; PSORIASIS VULGARIS; RECURRENT DISEASE; SCHOOL CHILD; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; AGED; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; DENMARK; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FEMALE; HUMANS; LUXEMBOURG; MALE; MIDDLE AGED; NETHERLANDS; OINTMENTS; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SWEDEN; TREATMENT OUTCOME;

EID: 73249147427     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2009.0767     Document Type: Article

References (18)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-50.
2. Guenther L. Fixed-dose combination therapy for psoriasis. Am J Clin Dermatol 2004; 5: 71-7.
3. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/ betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venerol 2002; 82: 131-5.
4. Guenther L, Cambazard F, Van de Kerkhof PC, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-23.
5. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone combination is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-93.
6. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-73.
7. Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/ Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; 213: 319-26.
8. van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004; 151: 663-8.
9. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Draft guideline. Feb 2006. http://www.fda.gov/CDER/guidance/5460dft.pdf
10. Koo JK, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-9.
11. Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 2006; 45: 970-5.
12. van de Kerkhof PC, Wasel N, Kragballe K, et al. A twocompound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology 2005; 210: 294-9.
13. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, et al. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol 2003; 148: 1153-60.
14. Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141: 1067-75.
15. Bottomley JM, Auland ME, Morais J, et al. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Curr Med Res Opin 2007; 23: 1887-901.
16. Peeters P, Ortonne JP, Sitbon R, et al. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris. Dermatology 2005; 211: 139-45.
17. Augustin M, Peeters P, Radtke M, et al. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/ Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone. Dermatology 2007; 215: 219-28.
18. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-60.